PURPOSE: To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an in vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling and simulation approach (Simcyp®). METHODS: Tramadol metabolism data was gathered using metabolite formation in human liver microsomes (HLM) and recombinant enzyme systems (rCYP). Hepatic intrinsic clearance (CLintH) was (i) estimated from HLM corrected for specific CYP450 contributions from a chemical inhibition assay (model 1); (ii) obtained in rCYP and corrected for specific CYP450 contributions by study-specific intersystem extrapolation factor (ISEF) values (model 2); and (iii) scaled back from in vivo observed clearance values (model 3). The model-predicted clearances of these three models were evaluated against observed clearance values in terms of relative difference of their geometric means, the fold difference of their coefficients of variation, and relative CYP2D6 contribution. RESULTS: Model 1 underpredicted, while model 2 overpredicted the total tramadol clearance by -27 and +22%, respectively. The CYP2D6 contribution was underestimated in both models 1 and 2. Also, the variability on the clearance of those models was slightly underpredicted. Additionally, blood-to-plasma ratio and hepatic uptake factor were identified as most influential factors in the prediction of the hepatic clearance using a sensitivity analysis. CONCLUSION: IVIVE-PBPK proved to be a useful tool in combining tramadol's low turnover in vitro metabolism data with system-specific physiological information to come up with reliable PK predictions in adults.
PURPOSE: To predict the tramadol in vivo pharmacokinetics in adults by using in vitro metabolism data and an in vitro-in vivo extrapolation (IVIVE)-linked physiologically-based pharmacokinetic (PBPK) modeling and simulation approach (Simcyp®). METHODS:Tramadol metabolism data was gathered using metabolite formation in human liver microsomes (HLM) and recombinant enzyme systems (rCYP). Hepatic intrinsic clearance (CLintH) was (i) estimated from HLM corrected for specific CYP450 contributions from a chemical inhibition assay (model 1); (ii) obtained in rCYP and corrected for specific CYP450 contributions by study-specific intersystem extrapolation factor (ISEF) values (model 2); and (iii) scaled back from in vivo observed clearance values (model 3). The model-predicted clearances of these three models were evaluated against observed clearance values in terms of relative difference of their geometric means, the fold difference of their coefficients of variation, and relative CYP2D6 contribution. RESULTS: Model 1 underpredicted, while model 2 overpredicted the total tramadol clearance by -27 and +22%, respectively. The CYP2D6 contribution was underestimated in both models 1 and 2. Also, the variability on the clearance of those models was slightly underpredicted. Additionally, blood-to-plasma ratio and hepatic uptake factor were identified as most influential factors in the prediction of the hepatic clearance using a sensitivity analysis. CONCLUSION: IVIVE-PBPK proved to be a useful tool in combining tramadol's low turnover in vitro metabolism data with system-specific physiological information to come up with reliable PK predictions in adults.
Authors: Andrea N Edginton; Frank-Peter Theil; Walter Schmitt; Stefan Willmann Journal: Expert Opin Drug Metab Toxicol Date: 2008-09 Impact factor: 4.481
Authors: Patrick Poulin; Cornelis E C A Hop; Quynh Ho; Jason S Halladay; Sami Haddad; Jane R Kenny Journal: J Pharm Sci Date: 2012-08-13 Impact factor: 3.534
Authors: Haoming Zhang; Chitra Sridar; Cesar Kenaan; Hemali Amunugama; David P Ballou; Paul F Hollenberg Journal: J Pharmacol Exp Ther Date: 2011-06-09 Impact factor: 4.030
Authors: M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein Journal: Clin Pharmacol Ther Date: 2012-10 Impact factor: 6.875
Authors: Huybrecht T'jollyn; Jan Snoeys; An Vermeulen; Robin Michelet; Filip Cuyckens; Geert Mannens; Achiel Van Peer; Pieter Annaert; Karel Allegaert; Jan Van Bocxlaer; Koen Boussery Journal: AAPS J Date: 2015-07-25 Impact factor: 4.009
Authors: Huybrecht T'jollyn; Jan Snoeys; Jan Van Bocxlaer; Lies De Bock; Pieter Annaert; Achiel Van Peer; Karel Allegaert; Geert Mannens; An Vermeulen; Koen Boussery Journal: Eur J Drug Metab Pharmacokinet Date: 2017-06 Impact factor: 2.441
Authors: Lei Wang; ChienWei Chiang; Hong Liang; Hengyi Wu; Weixing Feng; Sara K Quinney; Jin Li; Lang Li Journal: Biomed Res Int Date: 2015-10-11 Impact factor: 3.411